Shannon Shirley
Family · Horse Cave, KYNPI 1235525809
Payments from drug & device makers
Across 182 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$701
- GSK$359
- Lilly USA, LLC$287
- Novo Nordisk$223
- Pfizer$220
- Otsuka America Pharmaceutical, Inc.$145
- plus $895 from 24 others
What the payments were for
- Food & beverage$2,817100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $701 |
| GSK | 20 | $359 |
| Lilly USA, LLC | 20 | $287 |
| Novo Nordisk | 13 | $223 |
| Pfizer | 12 | $220 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Novartis | 6 | $94 |
| Xeris Pharmaceuticals, Inc. | 5 | $94 |
| Dexcom, Inc. | 5 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $83 |
| Boehringer Ingelheim | 4 | $59 |
| Bayer | 3 | $51 |
| Amgen | 3 | $46 |
| Lundbeck LLC | 2 | $45 |
| Medtronic | 2 | $40 |
| Insulet Corporation | 2 | $34 |
| Exact Sciences | 2 | $30 |
| Corcept Therapeutics | 2 | $29 |
| Johnson & Johnson | 1 | $21 |
| Bioxcel Therapeutics, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$113
How this compares
$2,829 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 104 | $116,266 |
| FarxigaDapagliflozin Propanediol | 140 | $104,901 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $80,422 |
| TradjentaLinagliptin | 116 | $79,600 |
| MounjaroTirzepatide | 66 | $73,619 |
| JardianceEmpagliflozin | 88 | $73,446 |
| JanuviaSitagliptin Phosphate | 78 | $63,683 |
| EliquisApixaban | 60 | $56,695 |
| RybelsusSemaglutide | 42 | $49,101 |
| VascepaIcosapent Ethyl | 83 | $48,098 |
| TrulicityDulaglutide | 33 | $46,254 |
| XareltoRivaroxaban | 35 | $31,359 |
| VraylarCariprazine Hcl | 22 | $30,500 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $21,232 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $223 | $165,366146 claims |
| Boehringer IngelheimTradjenta, Jardiance | $59 | $153,046204 claims |
| Lilly USA, LLCMounjaro, Trulicity | $287 | $119,87399 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $359 | $91,553151 claims |
| PfizerEliquis | $220 | $56,69560 claims |
| AbbVieVraylar, Synthroid | $701 | $32,97075 claims |
| Johnson & JohnsonXarelto | $21 | $31,35935 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $7,41713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Horse Cave
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.